Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian clinical-stage drug development company dedicated to developing Focal Adhesion Kinase (FAK) inhibitors for the treatment of cancer and fibrotic diseases. The company's mission is to address unmet medical needs in oncology and serious fibrotic conditions. Headquartered in Melbourne, Australia, Amplia Therapeutics focuses on advancing its proprietary drug candidates through clinical development.

The company's pipeline primarily features two drug candidates: narmafotinib (AMP945) and AMP886. Narmafotinib, a highly selective FAK inhibitor, is currently in Phase 2 clinical trials for pancreatic cancer, in clinical development for ovarian cancer, and in advanced preclinical development for idiopathic pulmonary fibrosis (IPF). It has received Orphan Drug Designations for pancreatic cancer and IPF from the US FDA, and an Investigational New Drug (IND) application has been cleared for a pancreatic cancer trial in the US. AMP886, the second pipeline drug, inhibits FAK along with VEGFR3 and FLT3, and is being evaluated in preclinical models of cancer.

Recent developments include the reporting of mature data from the ACCENT clinical trial in March 2026, which demonstrated a median overall survival of 11.1 months and five complete responses in advanced pancreatic cancer patients treated with narmafotinib combined with chemotherapy. In April 2026, Amplia halted recruitment for its AMPLICITY trial, investigating narmafotinib with FOLFIRINOX for pancreatic cancer, due to chemotherapy-related toxicities, while patients already enrolled continue treatment. The company also announced the opening of US sites for the AMPLICITY trial in February 2026 and successfully completed an A$25 million institutional placement in July 2025 to support its clinical programs. Dr. Chris Burns serves as the CEO and Managing Director.